Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 Congress
- Friday, June 10, 2022, 7:04
- Finance
- Add a comment
Data supports further development of CYT-338 in relapsed/refractory multiple myeloma AVENTURA, Fla. and NATICK, Mass., June 10, 2022 /PRNewswire/ — Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering…
About the Author
adminasapcorp has written 42199 stories on this site.